[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG11201906540WA - Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci - Google Patents

Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci

Info

Publication number
SG11201906540WA
SG11201906540WA SG11201906540WA SG11201906540WA SG11201906540WA SG 11201906540W A SG11201906540W A SG 11201906540WA SG 11201906540W A SG11201906540W A SG 11201906540WA SG 11201906540W A SG11201906540W A SG 11201906540WA SG 11201906540W A SG11201906540W A SG 11201906540WA
Authority
SG
Singapore
Prior art keywords
international
pct
road
heavy chain
human antibodies
Prior art date
Application number
SG11201906540WA
Inventor
Roland Buelow
Marianne Bruggemann
Biao Ma
Michael Osborn
Original Assignee
Open Monoclonal Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Open Monoclonal Tech Inc filed Critical Open Monoclonal Tech Inc
Publication of SG11201906540WA publication Critical patent/SG11201906540WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Environmental Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 26 July 2018 (26.07.2018) WIP0 I PCT IiiimmomiolollmonolomoilimuioloilionovoimIE (10) International Publication Number WO 2018/136823 Al (51) International Patent Classification: A01K 67/027 (2006.01) CO7K 16/00 (2006.01) (21) International Application Number: PCT/US2018/014568 (22) International Filing Date: (25) Filing Language: (26) Publication Language: (30) Priority Data: 62/448,317 (71) Applicant: OPEN MONOCLONAL TECHNOLOGY, INC. [US/US]; 3911 Sorrento Valley Boulevard, Suite 110, San Diego, CA 92121 (US). (72) Inventors: BUELOW, Roland; 2747 Ross Road, Palo Al- to, CA 94303 (US). BRUGGEMANN, Marianne; 2 Sta- tion Road, Fexton, Cambridge CB22 6SA (GB). MA, Biao; Top Floor Flat, 99 Hills Road, Cambridge CB2 1PG (GB). OSBORN, Michael, J.; Jasmine Cottage, Sturmer, Haver- hill, Suffolk CB9 7XF (GB). - ( 74 ) Agent: LORENZ, Todd, A. et al.; Arnold & Porter Kaye Scholer Llp, Three Embarcadero Center, 10th Floor, San Francisco, CA 94111 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) 19 January 2018 (19.01.2018) English English 19 January 2017 (19.01.2017) US - (54) Title: HUMAN ANTIBODIES FROM TRANSGENIC RODENTS WITH MULTIPLE HEAVY CHAIN IMMUNOGLOBULIN LOCI FIC14 (OmniRat 1) Hu BAC6-3 182 kb AsiSI-Ascl _ 10.0 kb Hu BAC3 173 kb Notl D1-1 D7-27 —Tt - (7 - 2;E; - ,1.3 kb Hu-Rat Annabel 193 kb Notl W O 20 18/1368 23 Al op Ov1 6y2b HC1 4 (Osborn et at, JO HC30 HC14/1-1C30 occasionally found in pale color t t tt tt .t tt t t t t tttt t t t tt ft t tf t t t t tttt t FIG. IA (57) : The invention relates to transgenic animals useful for optimal production of functional immunoglobulins with human idiotypes.
SG11201906540WA 2017-01-19 2018-01-19 Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci SG11201906540WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762448317P 2017-01-19 2017-01-19
PCT/US2018/014568 WO2018136823A1 (en) 2017-01-19 2018-01-19 Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci

Publications (1)

Publication Number Publication Date
SG11201906540WA true SG11201906540WA (en) 2019-08-27

Family

ID=61274322

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201906540WA SG11201906540WA (en) 2017-01-19 2018-01-19 Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
SG10202109874V SG10202109874VA (en) 2017-01-19 2018-01-19 Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202109874V SG10202109874VA (en) 2017-01-19 2018-01-19 Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci

Country Status (10)

Country Link
US (1) US12016313B2 (en)
EP (1) EP3570668A1 (en)
JP (2) JP2020505037A (en)
KR (1) KR20190104400A (en)
CN (2) CN110662421B (en)
AU (1) AU2018210420B2 (en)
CA (1) CA3050715A1 (en)
IL (1) IL268049A (en)
SG (2) SG11201906540WA (en)
WO (1) WO2018136823A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201906540WA (en) 2017-01-19 2019-08-27 Open Monoclonal Tech Inc Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
CA3125380A1 (en) 2019-02-18 2020-08-27 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with humanized immunoglobulin locus
CN115667532A (en) 2020-06-02 2023-01-31 百奥赛图(北京)医药科技股份有限公司 Genetically modified non-human animals with a common light chain immunoglobulin locus
CN114634932B (en) * 2022-03-11 2023-09-05 安徽医科大学 Novel circRNA, kit and application
WO2023192936A2 (en) * 2022-03-30 2023-10-05 Fred Hutchinson Cancer Center Systems and methods to produce b cells that express selected antibodies and gene products

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1571428A1 (en) 1966-08-18 1970-12-10 Domus Hartbeton Richard Bauer Mortar mix and method and device for its production
DE1938727A1 (en) 1969-07-30 1971-02-04 Vestische Glashuette Gmbh Ceramic stone and method of its manufacture
US3746678A (en) 1971-09-13 1973-07-17 Dow Chemical Co Amine-modified polyalkylene oxides
DE2152880A1 (en) 1971-10-23 1973-04-26 Kloeckner Humboldt Deutz Ag AGRICULTURAL AND CONSTRUCTION INDUSTRY USEFUL MULTI-PURPOSE VEHICLE
IT1045023B (en) 1972-07-12 1980-04-21 Ignitron Spa DEVICE FOR ELECTRONIC IGNITION WITH CAPACITIVE DISCHARGE HIGH VOLTAGE COIL INCORPORATED PARTICULARLY FOR MOTOR VEHICLE ENGINES
DE7540882U (en) 1975-12-22 1976-04-29 Hoechst Ag, 6000 Frankfurt RECEPTION DEVICE FOR REELING SLEEVES WITH TAPE-SHAPED MATERIAL
DE2602323A1 (en) 1976-01-22 1977-07-28 Asf Gleitverschluss Gmbh Plastics profiled ledge bag closure - has hook shaped insertion pin snapped into circular section female with corresponding shaped receiving groove
DE3020864A1 (en) 1980-06-02 1981-12-10 Henkel KGaA, 4000 Düsseldorf ADHESIVES AND / OR COATING MEASURES BASED ON ALKALI METAL SILICATE SOLUTIONS
GB2152880B (en) 1984-01-18 1987-08-19 Gillette Co Nibs
US4559377A (en) 1984-04-27 1985-12-17 Owens-Corning Fiberglas Corporation Ceiling board edge coating
FR2602323B1 (en) 1986-07-31 1990-04-27 Stein Heurtey PROCESS AND INSTALLATION FOR PREHEATING, IN A COOKING OVEN, CARBON PRODUCTS, SUCH AS ELECTRODES
US4977081A (en) 1987-05-04 1990-12-11 Adi Diagnostics, Inc. Stable rabbit-mouse hybridomas and secretion products thereof
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE3905268A1 (en) 1989-02-21 1990-08-23 Basf Lacke & Farben METHOD FOR COATING FINISH FILMS AND CONTINUOUS EDGES
FR2646438B1 (en) 1989-03-20 2007-11-02 Pasteur Institut A METHOD FOR SPECIFIC REPLACEMENT OF A COPY OF A GENE PRESENT IN THE RECEIVER GENOME BY INTEGRATION OF A GENE DIFFERENT FROM THAT OR INTEGRATION
US5574205A (en) 1989-07-25 1996-11-12 Cell Genesys Homologous recombination for universal donor cells and chimeric mammalian hosts
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
DE69120146T2 (en) 1990-01-12 1996-12-12 Cell Genesys Inc GENERATION OF XENOGENIC ANTIBODIES
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE175234T1 (en) 1990-07-10 1999-01-15 Nippon Kokan Kk POULTRY-SPECIFIC IMMUNOGLOBULIN G PRODUCING HYBRIDOMAS
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE158021T1 (en) 1990-08-29 1997-09-15 Genpharm Int PRODUCTION AND USE OF NON-HUMAN TRANSGENT ANIMALS FOR THE PRODUCTION OF HETEROLOGUE ANTIBODIES
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
AU664976B2 (en) 1990-08-29 1995-12-14 Gene Pharming Europe Bv Homologous recombination in mammalian cells
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0495423A3 (en) 1991-01-17 1993-01-13 Siemens Aktiengesellschaft Oesterreich Device for the multiple use of subscriber lines
AU675661B2 (en) 1992-07-24 1997-02-13 Abgenix, Inc. Generation of xenogeneic antibodies
EP0583980A1 (en) 1992-08-20 1994-02-23 Eli Lilly And Company Method for generating monoclonal antibodies from rabbits
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
PT1621554E (en) 1992-08-21 2009-07-13 Univ Bruxelles Immunoglobulins devoid of light chains
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
CA2761116A1 (en) 1995-04-27 1996-10-31 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
WO1997016537A1 (en) 1995-10-30 1997-05-09 Spectral Diagnostics, Inc. Stable chicken b-cell line and method of use thereof
US5716081A (en) 1996-03-11 1998-02-10 Automotive Products (Usa), Inc. Spring clip for quick connect coupling
WO1998024893A2 (en) 1996-12-03 1998-06-11 Abgenix, Inc. TRANSGENIC MAMMALS HAVING HUMAN IG LOCI INCLUDING PLURAL VH AND Vλ REGIONS AND ANTIBODIES PRODUCED THEREFROM
US6077593A (en) 1998-04-17 2000-06-20 Armstrong World Industries, Inc. Durable edge ceiling board
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
US6372956B1 (en) 1998-12-31 2002-04-16 The J. David Gladstone Institutes Transgenic rats and rat cell lines expressing human CD4 and a human chemokine receptor
ES2152880B1 (en) 1999-03-02 2001-08-16 Amper Sa DUPLICATOR OF SUBSCRIBER LINES FOR ISDN CENTERS
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
AU2001255613B2 (en) 2000-04-24 2005-08-04 Wyeth Transgenic animal
AU8470301A (en) 2000-08-03 2002-02-18 Wim-Van Schooten Production of humanized antibodies in transgenic animals
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
EP1420637A4 (en) 2001-08-20 2005-11-30 Merck & Co Inc Transgenic rodents as animal models for modulation of b 1? bradykinin receptor protein
JP4436130B2 (en) 2001-09-14 2010-03-24 セレクティス Random incorporation of polynucleotides by in vitro linearization
CA2468565C (en) 2001-11-30 2014-06-03 Abgenix, Inc. Transgenic animals bearing human iglambda light chain genes
AU2003251286B2 (en) 2002-01-23 2007-08-16 The University Of Utah Research Foundation Targeted chromosomal mutagenesis using zinc finger nucleases
EP1485475B2 (en) 2002-03-15 2017-09-20 Cellectis Hybrid and single chain meganucleases and use thereof
ATE531796T1 (en) 2002-03-21 2011-11-15 Sangamo Biosciences Inc METHODS AND COMPOSITIONS FOR USING ZINC FINGER ENDONUCLEASES TO IMPROVE HOMOLOGOUS RECOMBINATION
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
CA2514517A1 (en) 2003-01-28 2004-08-12 Cellectis Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof
EP1588592B1 (en) 2003-01-31 2009-12-09 Dow Corning Ireland Limited Plasma generating electrode assembly
US20040158880A1 (en) 2003-02-05 2004-08-12 Roland Buelow Suppression of endogenous immunoglobulin expression in transgenic non-human animals expressing humanized or human antibodies
GB2398784B (en) 2003-02-26 2005-07-27 Babraham Inst Removal and modification of the immunoglobulin constant region gene cluster of a non-human mammal
WO2005014650A2 (en) 2003-06-16 2005-02-17 Celltech R & D, Inc. Antibodies specific for sclerostin and methods for increasing bone mineralization
US7585668B2 (en) 2003-07-15 2009-09-08 Therapeutic Human Polyclonals, Inc. Humanized immunoglobulin loci
AU2003259718A1 (en) 2003-08-07 2005-03-07 Epitomics, Inc. Methods for humanizing rabbit monoclonal antibodies
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
WO2005019463A1 (en) 2003-08-11 2005-03-03 Therapeutic Human Polyclonals, Inc. Improved transgenesis with humanized immunoglobulin loci
WO2005038001A2 (en) 2003-10-14 2005-04-28 Therapeutic Human Polyclonals, Inc. Improved transgenesis by sperm-mediated gene transfer
KR20120091471A (en) 2004-03-04 2012-08-17 도쿠리츠교세이호진 고쿠리츠간켄큐센터 Rat embryonic stem cell
LT2311874T (en) 2004-07-22 2017-11-27 Erasmus University Medical Center Rotterdam Binding molecules
PT1802193E (en) 2004-10-19 2014-06-23 Regeneron Pharma Method for generating a mouse homozygous for a genetic modification
CN101084317A (en) * 2004-10-22 2007-12-05 人类多克隆治疗公司 Suppression of endogenous immunoglobulin expression
JPWO2006093337A1 (en) 2005-03-03 2008-08-07 武田薬品工業株式会社 Cancer preventive / therapeutic agent
WO2006097784A1 (en) 2005-03-15 2006-09-21 Cellectis I-crei meganuclease variants with modified specificity, method of preparation and uses thereof
JP2008535484A (en) 2005-03-15 2008-09-04 セレクティス Specificity-modified I-CreI meganuclease mutant, its production method and use thereof
US7491866B2 (en) 2005-11-09 2009-02-17 Board Of Regents University Of Texas System Transgenic rats and spermatogonial stem cells
SG169348A1 (en) 2006-01-25 2011-03-30 Univ Erasmus Medical Ct Generation of heavy-chain only antibodies in transgenic animals
EP2505058A1 (en) 2006-03-31 2012-10-03 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
SG174053A1 (en) * 2006-09-01 2011-09-29 Therapeutic Human Polyclonals Inc Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
JP5524627B2 (en) 2007-02-19 2014-06-18 セレクティス LAGLIDADG homing endonuclease variant with novel substrate specificity and use thereof
KR101886610B1 (en) 2007-06-01 2018-08-09 오픈 모노클로날 테크놀로지, 인코포레이티드 Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies
US9693539B2 (en) 2007-08-10 2017-07-04 E. R. Squibb & Sons, L.L.C. HCO32 and HCO27 and related examples
PL2209920T3 (en) 2007-11-01 2017-01-31 Self-Screen B V NEW DETECTION METHOD FOR CERVICAL HPVs
FR2931030B1 (en) 2008-05-16 2010-04-23 Robert Maumejean TRAILER WITH CHARGE REPORT
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US8772008B2 (en) 2009-05-18 2014-07-08 Sangamo Biosciences, Inc. Methods and compositions for increasing nuclease activity
DK2564695T3 (en) 2009-07-08 2015-05-26 Kymab Ltd Animal models and therapeutic molecules
WO2011156430A2 (en) 2010-06-07 2011-12-15 Fred Hutchinson Cancer Research Center Generation and expression of engineered i-onui endonuclease and its homologues and uses thereof
AU2011266843C9 (en) 2010-06-17 2018-03-01 Kymab Limited Animal models and therapeutic molecules
EP2947151A1 (en) 2010-08-02 2015-11-25 Regeneron Pharmaceuticals, Inc. Binding proteins comprising vl domains
WO2012063048A1 (en) 2010-11-08 2012-05-18 Kymab Limited Cells & vertebrates for enhanced somatic hypermutation and class switch recombination
WO2012149470A1 (en) 2011-04-27 2012-11-01 Amyris, Inc. Methods for genomic modification
WO2013096142A1 (en) 2011-12-20 2013-06-27 Regeneron Pharmaceuticals, Inc. Humanized light chain mice
EP3031921A1 (en) 2012-12-12 2016-06-15 The Broad Institute, Inc. Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
CN110042105B (en) 2012-12-14 2023-03-28 欧莫诺艾比公司 Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same
RU2690352C2 (en) 2013-02-20 2019-05-31 Регенерон Фармасютикалс, Инк. Genetic modification of rats
CN103205426B (en) 2013-03-08 2014-07-30 青岛市畜牧兽医研究所 DNA (deoxyribonucleic acid) segment capable of being identified by NF-kB transcription factors in pig species, recombinant vector and application of DNA segment
WO2014141189A1 (en) 2013-03-14 2014-09-18 Erasmus University Medical Center Transgenic non-human mammal for antibody production
DK2986729T3 (en) 2013-04-16 2018-10-29 Regeneron Pharma TARGETED MODIFICATION OF ROOT THROUGH
CA2910427C (en) 2013-05-10 2024-02-20 Sangamo Biosciences, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
BR112016013400B1 (en) 2013-12-11 2023-02-14 Regeneron Pharmaceuticals, Inc. IN VITRO METHOD TO MODIFY A GENOME AT A GENOMIC LOCUS OF INTEREST IN A PLURIPOTENT CELL
EP3083958B1 (en) 2013-12-19 2019-04-17 Amyris, Inc. Methods for genomic integration
WO2015127439A1 (en) 2014-02-24 2015-08-27 Sangamo Biosciences, Inc. Methods and compositions for nuclease-mediated targeted integration
JO3701B1 (en) 2014-05-23 2021-01-31 Regeneron Pharma Human antibodies to middle east respiratory syndrome – coronavirus spike protein
EP3152312B1 (en) 2014-06-06 2020-02-12 Regeneron Pharmaceuticals, Inc. Methods and compositions for modifying a targeted locus
EP3234200B1 (en) 2014-12-20 2021-07-07 Arc Bio, LLC Method for targeted depletion of nucleic acids using crispr/cas system proteins
EP3353309A4 (en) 2015-09-25 2019-04-10 Tarveda Therapeutics, Inc. Compositions and methods for genome editing
CN105274116B (en) 2015-10-21 2020-09-29 重庆金迈博生物科技有限公司 Nucleic acid molecule for preparing humanized antibody and application thereof
WO2017173092A1 (en) 2016-03-31 2017-10-05 The Regents Of The University Of California Methods for genome editing in zygotes
SG11201906540WA (en) 2017-01-19 2019-08-27 Open Monoclonal Tech Inc Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
US11519004B2 (en) 2018-03-19 2022-12-06 Regeneran Pharmaceuticals, Inc. Transcription modulation in animals using CRISPR/Cas systems
US20220323641A1 (en) 2019-08-20 2022-10-13 Theradaptive, Inc. Materials for delivery of tetherable proteins in bone implants

Also Published As

Publication number Publication date
CN110662421A (en) 2020-01-07
JP2020505037A (en) 2020-02-20
CN110662421B (en) 2023-03-24
AU2018210420B2 (en) 2024-08-01
IL268049A (en) 2019-09-26
EP3570668A1 (en) 2019-11-27
JP2023155267A (en) 2023-10-20
SG10202109874VA (en) 2021-10-28
WO2018136823A1 (en) 2018-07-26
CN118140872A (en) 2024-06-07
US20200163316A1 (en) 2020-05-28
CA3050715A1 (en) 2018-07-26
US12016313B2 (en) 2024-06-25
AU2018210420A1 (en) 2019-08-08
KR20190104400A (en) 2019-09-09

Similar Documents

Publication Publication Date Title
SG11201906540WA (en) Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
SG11201808772WA (en) Meta-lenses for sub-wavelength resolution imaging
SG11201807437XA (en) Antibodies specific to human poliovirus receptor (pvr)
SG11201804787UA (en) Human immunodeficiency virus neutralizing antibodies
SG11201810697QA (en) Chimeric antigen receptor and car-t cells that bind bcma
SG11201908971RA (en) Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201807279QA (en) Binding proteins and methods of use thereof
SG11201908051RA (en) Modified human igm constant regions for modulation of complement-dependent cytolysis effector function
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201805420SA (en) Antibodies and conjugates thereof
SG11201809041TA (en) Compositions and methods for selective protein expression
SG11201901307VA (en) Heterodimeric immunoglobulin constructs and preparation methods thereof
SG11201407644UA (en) Methods for making fully human bispecific antibodies using a common light chain
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201808076UA (en) Facilitating vehicle driving and self-driving
SG11201908179UA (en) Aryl cyclopropyl-amino-isoquinolinyl amide compounds
SG11201908056QA (en) Anti-par2 antibodies and uses thereof
SG11201907948TA (en) Formulations comprising pd-1 binding proteins and methods of making thereof
SG11201902873RA (en) Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide y receptors
SG11201908678XA (en) Methods and compositions for reduction of immunogenicity
SG11201807597UA (en) Methods of treating depression using orexin-2 receptor antagonists
SG11201807794VA (en) Naphthene-containing distillate stream compositions and uses thereof
SG11201908238SA (en) Anti-c5 antibodies and uses thereof
SG11201907583TA (en) Methods for treating complement-mediated diseases and disorders